Find Clinical Trials | Cedars-Sinai

162 results found

Cervix

NRG, NRG-GY032, Ph2,Open-Label, Early Stage Endometrial Cancer, De-escalated adjuv or observation

Primary Objective Estimate the rate of pelvic recurrence at 3 years in patients who are treated with a de-escalated adjuvant treatment directed by tumor molecular status. Secondary Objectives Estimate the rate of isolated vaginal recurrence, para-aortic ...

Lymphoid Leukemia, Non-Hodgkin Lymphoma

Comparing Rituximab and Mosunetuzumab in Low Tumor Burden Follicular Lymphoma

The purpose of this study is to compare the usual treatment (rituximab) to an experimental drug called mosunetuzumab in people with low tumor burden follicular lymphoma. Mosunetuzumab is a type of drug known as a ...

Bones and Joints, Breast, Cervix, Colon, Esophagus, Kidney, Liver, Lung ...

MacroGenics, Inc., CP-MGC026-01, Phase 1/1b, Open Label, Multi-Center, Solid Tumors, MGC026

Primary Objective: To characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGC026. Secondary Objective(s): To characterize the systemic pharmacokinetics (PK) of ...

Other Female Genital, Unknown Sites

Neratinib Alone or in Combination with Palbociclib in HER2+ Cancers and Other Solid Tumors

This study focuses on individuals who have recurrent or persistent cancer and whose cancer expresses a protein called HER2 (human growth factor receptor 2). The purpose of the study is to determine whether a combination ...

Breast

Adjuvant Sacituzumab Govitecan and Pembrolizumab in Triple-Negative Breast Cancer

The purpose of this study is to evaluate an experimental drug called sacituzumab govitecan in combination with pembrolizumab, or pembrolizumab with or without capecitabine, in people with high-risk, early triple-negative breast cancer without mutations (changes) ...